Valuation: GENFIT

Market Cap 421M 470M 392M 356M 671M 44.93B 675M 4.71B 1.85B 23.19B 1.77B 1.73B 74.61B P/E 2026 *
9.8x
P/E 2027 * 89.9x
Enterprise Value 281M 314M 262M 238M 448M 29.99B 451M 3.15B 1.23B 15.48B 1.18B 1.15B 49.81B EV / Sales 2026 *
2.59x
EV / Sales 2027 * 2.72x
Free-Float
86.79%
Yield 2026 *
-
Yield 2027 * -
1 day+1.57%
1 week-8.88%
Current month-15.22%
1 month-35.41%
3 months-38.79%
6 months-3.11%
Current year+59.73%
1 week 8.15
Extreme 8.15
9.31
1 month 8.15
Extreme 8.15
13.16
Current year 5.05
Extreme 5.05
15.48
1 year 3.4
Extreme 3.4
15.48
3 years 2.62
Extreme 2.62
15.48
5 years 2.62
Extreme 2.62
15.48
10 years 2.62
Extreme 2.62
35.65
Manager TitleAgeSince
Chief Executive Officer 58 2019-09-15
Director of Finance/CFO 52 2021-04-21
Chief Tech/Sci/R&D Officer - 2025-11-26
Director TitleAgeSince
Chairman 70 2017-06-15
Director/Board Member 54 1999-09-14
Director/Board Member 58 2017-06-15
Date Insider Type Main position Quantity % Market Cap. Importance
3/5/26 Exercice

Chief Operating Officer

11,250 0.0225%
3/5/26 Exercice

Chief Operating Officer

7,083 0.0142%
3/5/26 Sell

Chief Operating Officer

7,083 0.0142%
Change 5-day change 1-year change 3-year change Capi.($)
+1.57%-8.88%+124.51%+168.26% 464M
+0.03%-5.67%+50.74%+76.76% 70.61B
+0.66%-9.75%+6.97%+52.62% 51.01B
+0.31%-0.14%+8.84%+32.99% 48.1B
+0.90%-1.46%+32.32%+32.69% 42.78B
+2.21%-6.61%+302.05%+701.45% 40.67B
-1.15%-3.11%+9.47%+98.83% 40.3B
+0.45%-1.20%+9.11%+43.54% 30.59B
-3.13%-12.09%+41.15%+3.67% 28.16B
-1.16%-1.84%-6.09%-11.99% 24.36B
Average +0.05%-3.42%+57.91%+119.88% 37.7B
Weighted average by Cap. +0.07%-2.98%+52.41%+118.88%

Financials

2026 *2027 *
Net sales 109M 121M 101M 91.75M 173M 11.59B 174M 1.22B 476M 5.98B 455M 445M 19.24B 130M 145M 121M 110M 207M 13.87B 208M 1.45B 570M 7.16B 545M 533M 23.03B
Net income 42.71M 47.71M 39.82M 36.11M 68.12M 4.56B 68.54M 478M 187M 2.35B 179M 175M 7.57B 10.37M 11.58M 9.66M 8.77M 16.53M 1.11B 16.64M 116M 45.46M 571M 43.5M 42.54M 1.84B
Net Debt -140M -156M -130M -118M -223M -14.94B -224M -1.57B -613M -7.71B -587M -574M -24.8B -67.56M -75.47M -62.98M -57.12M -108M -7.21B -108M -757M -296M -3.72B -283M -277M -11.98B
Projected Income Statement - Annual - GENFIT
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
180
Date Price Change Volume
26-10-12 €8.410 +1.57% 322,623
26-10-09 €8.280 -0.60% 376,719
26-10-08 €8.330 -8.66% 509,932
26-10-07 €9.120 -1.94% 239,980
26-10-06 €9.300 +0.76% 265,341
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - GENFIT
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.410EUR
Average target price
17.48EUR
Spread / Average Target
+107.85%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - GENFIT
  1. Stock Market
  2. Stocks
  3. GNFT Stock